The Fatty Liver Disease Clinic, directed by Dr. Hari Conjeevaram, is involved in the research of non-alcoholic fatty liver disease (NAFLD) including studying factors that predict disease severity and clinical management of NAFLD. Currently, there are ongoing clinical studies in the management of NAFLD using PPAR-alfa agonist fenofibrate and recombinant leptin. We are planning to prospectively study the long-term outcomes of NAFLD in patients undergoing orthotopic liver transplantation.
In addition to NAFLD, the importance of steatosis and insulin resistance in patients with chronic viral hepatitis C is being studied in our program. We also have an ongoing study of PPAR-gamma agonist pioglitazone in improving insulin sensitivity, hepatic steatosis and virological response in patients with chronic hepatitis C genotype 1 infection.
We are also examining the mechanisms of hepatic steatosis in patients with NAFLD and those with chronic hepatitis C and hepatic steatosis. Specifically in chronic hepatitis C infection, we are studying to determine whether there is evidence of different lipid handling in the African American versus Caucasian population which may provide insight into the differences in the rates of insulin resistance, hepatic steatosis and response to therapy.
Location and contact numbers:
A. Alfred Taubman Health Center
Floor 3, Reception: D
1500 East Medical Center Drive, SPC 5362
Ann Arbor, MI 48109-5362